Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Serotonin transporter genomic biomarker for quantitative assessment of ondansetron treatment response in alcoholics.

Seneviratne C, Johnson BA.

Front Psychiatry. 2012 Mar 28;3:23. doi: 10.3389/fpsyt.2012.00023. eCollection 2012.

2.

Ondansetron reduces naturalistic drinking in nontreatment-seeking alcohol-dependent individuals with the LL 5'-HTTLPR genotype: a laboratory study.

Kenna GA, Zywiak WH, Swift RM, McGeary JE, Clifford JS, Shoaff JR, Vuittonet C, Fricchione S, Brickley M, Beaucage K, Haass-Koffler CL, Leggio L.

Alcohol Clin Exp Res. 2014 Jun;38(6):1567-74. doi: 10.1111/acer.12410. Epub 2014 Apr 28.

3.

Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking.

Johnson BA, Ait-Daoud N, Seneviratne C, Roache JD, Javors MA, Wang XQ, Liu L, Penberthy JK, DiClemente CC, Li MD.

Am J Psychiatry. 2011 Mar;168(3):265-75. doi: 10.1176/appi.ajp.2010.10050755. Epub 2011 Jan 19. Erratum in: Am J Psychiatry. 2011 Jul;168(7):756.

4.

Ondansetron and sertraline may interact with 5-HTTLPR and DRD4 polymorphisms to reduce drinking in non-treatment seeking alcohol-dependent women: exploratory findings.

Kenna GA, Zywiak WH, Swift RM, McGeary JE, Clifford JS, Shoaff JR, Fricchione S, Brickley M, Beaucage K, Haass-Koffler CL, Leggio L.

Alcohol. 2014 Sep;48(6):515-22. doi: 10.1016/j.alcohol.2014.04.005. Epub 2014 Aug 14.

5.

Determination of genotype combinations that can predict the outcome of the treatment of alcohol dependence using the 5-HT(3) antagonist ondansetron.

Johnson BA, Seneviratne C, Wang XQ, Ait-Daoud N, Li MD.

Am J Psychiatry. 2013 Sep;170(9):1020-31. doi: 10.1176/appi.ajp.2013.12091163.

6.

A within-group design of nontreatment seeking 5-HTTLPR genotyped alcohol-dependent subjects receiving ondansetron and sertraline.

Kenna GA, Zywiak WH, McGeary JE, Leggio L, McGeary C, Wang S, Grenga A, Swift RM.

Alcohol Clin Exp Res. 2009 Feb;33(2):315-23. doi: 10.1111/j.1530-0277.2008.00835.x. Epub 2008 Nov 19.

7.

Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial.

Johnson BA, Roache JD, Javors MA, DiClemente CC, Cloninger CR, Prihoda TJ, Bordnick PS, Ait-Daoud N, Hensler J.

JAMA. 2000 Aug 23-30;284(8):963-71.

PMID:
10944641
8.
9.

Prediction of serotonergic treatment efficacy using age of onset and Type A/B typologies of alcoholism.

Roache JD, Wang Y, Ait-Daoud N, Johnson BA.

Alcohol Clin Exp Res. 2008 Aug;32(8):1502-12. doi: 10.1111/j.1530-0277.2008.00717.x. Epub 2008 Jun 28.

10.

Combining ondansetron and naltrexone reduces craving among biologically predisposed alcoholics: preliminary clinical evidence.

Ait-Daoud N, Johnson BA, Prihoda TJ, Hargita ID.

Psychopharmacology (Berl). 2001 Feb;154(1):23-7.

PMID:
11292002
11.
12.

Platelet serotonin uptake and paroxetine binding among allelic genotypes of the serotonin transporter in alcoholics.

Javors MA, Seneviratne C, Roache JD, Ait-Daoud N, Bergeson SE, Walss-Bass MC, Akhtar FZ, Johnson BA.

Prog Neuropsychopharmacol Biol Psychiatry. 2005 Jan;29(1):7-13. Epub 2004 Nov 4.

13.

Can serotonin transporter genotype predict serotonergic function, chronicity, and severity of drinking?

Johnson BA, Javors MA, Roache JD, Seneviratne C, Bergeson SE, Ait-Daoud N, Dawes MA, Ma JZ.

Prog Neuropsychopharmacol Biol Psychiatry. 2008 Jan 1;32(1):209-16. Epub 2007 Aug 19.

14.

Ondansetron reduces mood disturbance among biologically predisposed, alcohol-dependent individuals.

Johnson BA, Ait-Daoud N, Ma JZ, Wang Y.

Alcohol Clin Exp Res. 2003 Nov;27(11):1773-9.

PMID:
14634493
15.

Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence.

Sellers EM, Toneatto T, Romach MK, Somer GR, Sobell LC, Sobell MB.

Alcohol Clin Exp Res. 1994 Aug;18(4):879-85.

PMID:
7978099
16.

Alcohol Dependence and Genetic Variability in the Serotonin Pathway among Currently and Formerly Alcohol-Dependent Males.

Plemenitas A, Kastelic M, o Porcelli S, Serretti A, Dol┼żan V, Kores Plesnicar B.

Neuropsychobiology. 2015;72(1):57-64.

PMID:
26352193
17.

Polymorphism in the serotonin transporter gene and response to treatment in African American cocaine and alcohol-abusing individuals.

Mannelli P, Patkar AA, Murray HW, Certa K, Peindl K, Mattila-Evenden M, Berrettini WH.

Addict Biol. 2005 Sep;10(3):261-8.

PMID:
16109588
18.

Ondansetron reduces the craving of biologically predisposed alcoholics.

Johnson BA, Roache JD, Ait-Daoud N, Zanca NA, Velazquez M.

Psychopharmacology (Berl). 2002 Apr;160(4):408-13. Epub 2002 Feb 12.

PMID:
11919668
19.

Relationship between serotonin transporter gene polymorphisms and platelet serotonin transporter sites among African-American cocaine-dependent individuals and healthy volunteers.

Patkar AA, Berrettini WH, Mannelli P, Gopalakrishnan R, Hoehe MR, Bilal L, Weinstein S, Vergare MJ.

Psychiatr Genet. 2004 Mar;14(1):25-32.

PMID:
15091312
20.

Effects of ondansetron in early- versus late-onset alcoholics: a prospective, open-label study.

Kranzler HR, Pierucci-Lagha A, Feinn R, Hernandez-Avila C.

Alcohol Clin Exp Res. 2003 Jul;27(7):1150-5.

PMID:
12878921

Supplemental Content

Support Center